Anti-PD-L1 monoclonal antibodyAstraZeneca
Durvalumab
Durvalumab (IMFINZI) is an anti-PD-L1 monoclonal antibody and a backbone of AstraZeneca's immuno-oncology franchise. It was combined with ceralasertib in the LATIFY NSCLC study.
Also known as: IMFINZI, MEDI4736
1
Trials tracked
0
Resolved
1
Indications
1
Targets
Durvalumab forecasting benchmarks
1 benchmarkMechanism & molecular targets
Indications studied
Developed by
About Durvalumab
What is Durvalumab?
Durvalumab (IMFINZI) is an anti-PD-L1 monoclonal antibody and a backbone of AstraZeneca's immuno-oncology franchise. It was combined with ceralasertib in the LATIFY NSCLC study. It is a anti-pd-l1 monoclonal antibody developed by AstraZeneca.
What does Durvalumab target?
Durvalumab acts on PD-L1 (CD274).
How well do AI models predict Durvalumab trial outcomes?
Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.